Actively Recruiting
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Led by Uma Borate · Updated on 2026-03-13
52
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
Sponsors
U
Uma Borate
Lead Sponsor
I
Incyte Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS) overlap or high risk chronic myelomonocytic leukemia (CMML). Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, this may slow or halt the growth of the cancer. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving axatilimab with or without azacitidine may be safe and effective in treating patients with advanced phase MPN, MPN/MDS overlap or high risk CMML.
CONDITIONS
Official Title
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent before joining the study
- Age 18 years or older at consent
- Confirmed diagnosis of relapsed/refractory or newly diagnosed advanced phase MPN, MPN/MDS overlap, or high-risk CMML as defined by WHO 2016
- Specific conditions include CMML (intermediate-2 or high-risk), atypical chronic myelocytic leukemia, MDS/MPN unclassified, myeloproliferative neoplasm accelerated phase with prior PV, ET, or PMF and intermediate-2/high risk, MDS/MPN with ring sideroblasts and thrombocytosis or with SF3B1 mutation
- Not suitable for immediate intensive chemotherapy based on age, health, or local guidelines
- ECOG performance status of 0, 1, or 2
- Liver enzymes (AST, ALT) no more than 3 times upper normal limit
- Total bilirubin no more than 1.5 times upper normal limit (except Gilbert syndrome)
- Kidney function (eGFR) at least 30 mL/min/1.73m²
- Able to communicate and comply with study requirements
- Women and men of childbearing potential must use effective contraception from 14 days before study entry until 90 days after last follow-up
You will not qualify if you...
- Prior treatment for MPN or MDS/MPN overlap with chemotherapy or antineoplastic agents except up to 2 cycles of hypomethylating agents; prior hydroxyurea or ruxolitinib allowed
- Diagnosis of acute myeloid leukemia including acute promyelocytic leukemia or extramedullary AML
- Candidates for intensive chemotherapy or unwilling to undergo it
- History of organ or stem cell transplant
- Previous malignancy except adequately treated cancers without ongoing therapy or therapy-related neoplasms
- Known allergy to axatilimab components
- History of acute or chronic pancreatitis
- History of myositis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
Research Team
T
The Ohio State University Comprehensive Cancer Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here